| Surveillance nanotechnology for multi-organ cancer metastases H Kantamneni, M Zevon, MJ Donzanti, X Zhao, Y Sheng, SR Barkund, ... Nature biomedical engineering 1 (12), 993-1003, 2017 | 55 | 2017 |
| FOXO3a gene polymorphism associated with asthma in Indian population S Barkund, T Shah, N Ambatkar, M Gadgil, K Joshi Molecular biology international 2015, 2015 | 25 | 2015 |
| Shortwave infrared emitting multicolored nanoprobes for biomarker-specific cancer imaging in vivo H Kantamneni, S Barkund, M Donzanti, D Martin, X Zhao, S He, ... BMC cancer 20, 1-12, 2020 | 10 | 2020 |
| Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing … W Abida, AW Hahn, N Shore, N Agarwal, P Sieber, MR Smith, T Dorff, ... Clinical Cancer Research, OF1-OF10, 2024 | 2 | 2024 |
| ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates robust in vivo activity in prostate cancer models A Daemen, JD Sun, A Pankov, FL Duong, N Yuen, S Barkund, S Kaushik, ... Cancer Research 81 (13), 2021 | 2 | 2021 |
| Abstract P015: Biomarker results supporting selection of RP2D from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in … A Daemen, S Barkund, A Johnson, A Pankov, AW Wang, H Zhou, ... Molecular Cancer Therapeutics 20 (12_Supplement), P015-P015, 2021 | 1 | 2021 |
| Biomarker results supporting selection of RP2D from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with … A Daemen, A Pankov, S Barkund, H Zhou, M Duff, A Johnson, R Xu, ... J Clin Oncol 39 (15_suppl), 3110, 2021 | 1 | 2021 |
| ORIC-101 comprehensively inhibits glucocorticoid pathways to overcome therapeutic resistance in pan-cancer models A Pankov, H Zhou, S Barkund, G Hegde, P Narayanan, O Kabbarah, ... Cancer Research 80 (16_Supplement), 4120-4120, 2020 | 1 | 2020 |
| Abstract P6-03-24: ORIC-101 robustly inhibits the glucocorticoid pathway and overcomes chemoresistance in triple-negative breast cancer H Zhou, Q Ye, A Pankov, W Kong, S Barkund, LS Friedman, JD Sun, ... Cancer Research 80 (4_Supplement), P6-03-24-P6-03-24, 2020 | 1 | 2020 |
| Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinations H Zhou, LS Friedman, S Barkund, A Daemen US Patent App. 18/007,369, 2023 | | 2023 |
| Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic prostate cancer A Daemen, N Yuen, A Pankov, EA Ariazi, SD Katewa, FL Duong, A Wang, ... Cancer Research 83 (7_Supplement), 2791-2791, 2023 | | 2023 |
| GR antagonist ORIC-101 overcomes GR-mediated resistance to the combination of AR and AKT inhibition in preclinical prostate cancer cell lines. S Barkund, H Zhou, LS Friedman, A Daemen Cancer Research 81 (13), 2021 | | 2021 |
| ORIC-101 overcomes GR-driven resistance to AR degradation in castration-resistant prostate cancer models H Zhou, S Barkund, LS Friedman, A Daemen European Journal of Cancer 138, S22, 2020 | | 2020 |
| ORIC-101 overcomes resistance to diverse chemotherapeutics across cancer types H Zhou, S Barkund, A Pankov, G Hegde, W Kong, P Narayanan, JD Sun, ... Cancer Research 80 (16_Supplement), 4121-4121, 2020 | | 2020 |
| ORIC-101 overcomes glucocorticoid receptor-mediated chemoresistance in pancreatic cancer models JD Sun, H Zhou, W Kong, N Yuen, F Duong, S Barkund, A Pankov, ... Cancer Research 80 (16), 2020 | | 2020 |
| ORIC-101 robustly inhibits the glucocorticoid pathway and overcomes chemoresistance in triple-negative breast cancer H Zhou, Q Ye, A Pankov, W Kong, S Barkund, LS Friedman, JD Sun, ... CANCER RESEARCH 80 (4), 2020 | | 2020 |
| Abstract LB-A10: ORIC-101 overcomes glucocorticoid-driven resistance to enzalutamide in castration-resistant prostate cancer H Zhou, S Barkund, A Pankov, S Sinha, D Sutimantanapi, LS Friedman, ... Molecular Cancer Therapeutics 18 (12 Supplement), LB-A10-LB-A10, 2019 | | 2019 |
